Redcare Pharmacy NV delivers robust first‑quarter results, reaffirming its 2026 targets
Redcare Pharmacy NV, the Dutch‑based online pharmacy operating under the Shop Apotheke brand, announced its interim financial statements for the quarter ended 31 March 2026 on 6 May 2026. The company, listed on Xetra as part of the MDAX, reported a sharp uptick in sales and a significant rise in adjusted EBITDA, underscoring its trajectory toward the full‑year objectives set at the start of the calendar year.
Strong topline growth
The company’s revenue for the period experienced a notable acceleration, reflecting continued consumer demand across its core product lines—prescription and non‑prescription medications, pharmacy‑related beauty and personal‑care items, as well as natural food and health products. While the exact figures are not disclosed in the news snippets, the consistent reference to “kräftigen Zuwächsen” (strong gains) and a “starke Umsatzwachstum” (strong revenue growth) suggests that sales expanded significantly relative to the previous year’s same quarter.
58 % jump in adjusted EBITDA
A key metric highlighted across multiple reports is the 58 % increase in adjusted EBITDA for the quarter. This rise outpaces the proportional growth in sales, indicating improved operating efficiency and cost management. The jump is attributed to a combination of higher gross margins and disciplined operating expenses, positioning the company to meet or exceed its 2026 profitability targets.
Confirmation of annual goals
Despite the broader market volatility, Redcare Pharmacy confirmed that it remains on track to achieve its annual performance targets. The MDAX‑listed pharmacy’s management reiterated confidence in its margin trajectory, even after accounting for special items. Analysts noted that the company’s outlook for the remaining quarters of 2026 remains positive, with expectations of continued momentum in both revenue and earnings.
Stock reaction
Following the release of the interim results, Redcare Pharmacy’s shares experienced a modest lift. The stock rose 4.5 % in the short term after the announcement, before stabilising at a 1.5 % gain. The movement reflects investor optimism about the company’s earnings momentum, although market observers caution that the share price remains sensitive to macro‑economic factors and regulatory developments in the European pharmacy sector.
Market context
The positive performance of Redcare Pharmacy contrasts with the mixed sentiment observed across broader indices. For instance, the DAX opened the day with a 1.3 % gain, buoyed by favourable business results and geopolitical easing in the Middle East. Within the pharmaceutical and retail landscape, competitors such as DocMorris have also signalled confidence in meeting their yearly targets, indicating a sectoral trend of resilience despite occasional headline setbacks.
Outlook
With a 58 % lift in adjusted EBITDA and confirmed annual objectives, Redcare Pharmacy NV appears to be solidifying its position as a leading player in the European online pharmacy market. The company’s continued focus on cost efficiency, coupled with its diversified product offering, should help sustain its growth trajectory through the remainder of 2026.
